Other lipid-lowering agents have been shown to be more or less effective as well (Figure 1), especially when used in combination regimens. [2] Yet, a large percentage of treated patients still ...

The researchers said: 'We found that lipid-lowering drugs, particularly statins, were associated with decreased risk of 21 ...

In this review we discuss evidence on the clinical benefit and safety of lipid-lowering agents for different stages of chronic kidney disease. Dyslipidemia is a well-established traditional risk ...

The Lipid-Lowering Agents market in Hungary is projected to witness a significant increase in revenue, reaching US$7.73m in 2024. This growth is expected to continue with an annual growth rate ...

The projected revenue for the Lipid-Lowering Agents market in Myanmar is expected to reach US$1.65m in 2024. With an annual growth rate (CAGR 2024-2029) of 0.00%, the market volume is estimated to ...

MONCYTE Health, a diagnostics company based in Helsinki, has raised €1 million in a seed funding round to advance its ...

The availability of multiple lipid-lowering drugs and supplements provides new opportunities for patients to achieve target lipid levels. However, the variety of therapeutic options poses a ...

Research has established that xanthelasma palpebrarum (XP), which is associated with yellowish cholesterol deposits on the ...

DelveInsight’s, “Peripheral Arterial Disease Pipeline Insight 2024” report provides comprehensive insights about 18+ ...

MONCYTE health diagnostics, developing proprietary technology to optimize treatment and prevention of cardiovascular disease, has closed a EUR 1 million seed round to fund its go-to-market strategy.